Literature DB >> 9874319

Long-term effects of immunosuppressants in steroid-dependent nephrotic syndrome.

A Takeda1, H Ohgushi, F Niimura, H Matsutani.   

Abstract

In order to elucidate long-term effects of immunosuppressants, we studied 60 children with steroid-dependent nephrotic syndrome who were treated with three immunosuppressants: cyclophosphamide (n=34), chlorambucil (n=11), and cyclosporin A (n=15). Each relapse before and after the administration of immunosuppressants was evaluated longitudinally in terms of the relapse-free period and the maintenance dose of prednisolone required. The median follow-up period after immunosuppressants was 5.2 years (range 0.5-20.3 years). The relapse-free period was significantly longer in all groups after the initiation of immunosuppressants. However, the relapse-free period after subsequent relapses as compared with the previous relapse was longer in the cyclophosphamide group, similar in the chlorambucil group, and shorter in the cyclosporin A group. The prednisolone dosage at relapse was reduced in subsequent relapses after cyclophosphamide and chlorambucil treatment, but tended to be higher in later relapses after the initiation of cyclosporin A. These findings suggest that the effects of cyclophosphamide are long lasting, while those of chlorambucil and cyclosporin A are of short duration. Children who relapse after cyclosporin A treatment may experience a worse relapsing course.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9874319     DOI: 10.1007/s004670050538

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

1.  Protective effect of astragalosides from Radix Astragali on adriamycin-induced podocyte injury.

Authors:  Yi-Pa Sai; Yuan-Chun Song; Xing-Xing Chen; Xuan Luo; Jing Liu; Wei-Jing Cui
Journal:  Exp Ther Med       Date:  2018-03-06       Impact factor: 2.447

2.  Nephrotoxicity of once-daily cyclosporine A in minimal change nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Daishi Hirano; Hitohiko Murakami; Yoshiyuki Ohtomo; Toshiaki Shimizu; Kazunari Kaneko
Journal:  Pediatr Nephrol       Date:  2011-12-24       Impact factor: 3.714

3.  Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.

Authors:  S Mendizábal; I Zamora; O Berbel; M J Sanahuja; J Fuentes; J Simon
Journal:  Pediatr Nephrol       Date:  2005-05-13       Impact factor: 3.714

4.  Transforming growth factor-beta1 in nephrotic syndrome treated with cyclosporine and ACE inhibitors.

Authors:  Anna M Wasilewska; Walentyna M Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2004-12       Impact factor: 3.714

5.  Cyclophosphamide in steroid-dependent nephrotic syndrome.

Authors:  Sonia Azib; Marie Alice Macher; Theresa Kwon; Agnes Dechartres; Corinne Alberti; Chantal Loirat; Georges Deschênes; Véronique Baudouin
Journal:  Pediatr Nephrol       Date:  2011-03-12       Impact factor: 3.714

6.  Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients.

Authors:  Teresinha L Donatti; Vera H Koch; Maria D Fujimura; Yassuhiko Okay
Journal:  Pediatr Nephrol       Date:  2003-05-16       Impact factor: 3.714

7.  Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome.

Authors:  Narayan Prasad; Sanjeev Gulati; Raj Kumar Sharma; Uttam Singh; Muffazal Ahmed
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.